Budd-Chiari syndrome (BCS) is a rare condition characterized by thrombotic obstruction of the hepatic venous outflow tract, from the small intrahepatic venules to the hepatic vein–IVC junction, resulting in sinusoidal congestion, portal hypertension, and progressive liver injury. [1-2] Incidence is 0.5–2 per million in Western countries and 5–7 per million in Asia. [3] It most commonly affects younger patients, with myeloproliferative neoplasms as the leading underlying cause (~40–50%). [2]
The following stepwise treatment algorithm from the NEJM review illustrates the standard management approach:
1. History
- Onset and tempo: Acute (days), subacute (weeks–months, most common), or chronic (months–years) [1][5]
- Abdominal pain: Right upper quadrant or diffuse; often the presenting complaint
- Abdominal distension: Rapid-onset ascites is a hallmark — ask about weight gain, increasing girth, early satiety
- GI bleeding: Hematemesis or melena from variceal bleeding
- Jaundice: Timing and progression
- Lower extremity swelling: Suggests IVC involvement
- Triggers: Recent pregnancy, postpartum period, new oral contraceptive use, recent abdominal surgery or trauma [2]
- Known hematologic disorders: Prior diagnosis of polycythemia vera, essential thrombocythemia, PNH, antiphospholipid syndrome
- Prior VTE history: DVT, PE, or splanchnic vein thrombosis
2. Alarm Features
- Fulminant liver failure: Encephalopathy, coagulopathy, rapidly rising bilirubin — occurs in a minority but carries high mortality (transplant-free survival historically 37–42%) [6]
- Massive ascites with renal failure (hepatorenal physiology)
- GI hemorrhage from variceal rupture
- Marked aminotransferase elevation (AST > ALT, often >1000 IU/L in acute BCS) [6]
- Signs of IVC obstruction: Bilateral lower extremity edema, dilated abdominal wall veins (caput medusae pattern extending to flanks/back, not just periumbilical)
- Hepatic encephalopathy at presentation
3. Medications
- Contributors/Triggers:
- Oral contraceptives — present in ~22% of BCS cases [2]
- Hormone replacement therapy
- Erythropoiesis-stimulating agents
- Treatments:
- LMWH (preferred initial anticoagulation) → transition to warfarin (VKA) for long-term therapy [2][7]
- Avoid long-term unfractionated heparin — high risk of heparin-induced thrombocytopenia in BCS [2][7]
- DOACs: Emerging data suggest safety and efficacy, but evidence remains limited; not yet standard of care [2][8]
- Diuretics (spironolactone ± furosemide) for ascites management
- Nonselective beta-blockers for variceal bleeding prophylaxis [2]
- Cytoreductive therapy (e.g., hydroxyurea) if underlying MPN identified [9]
- Cautions: Anticoagulation is recommended even in the absence of an identified prothrombotic disorder; most patients require lifelong anticoagulation [1-2][7]
4. Diet
- Sodium restriction (≤2 g/day) for ascites management
- Adequate protein intake to prevent malnutrition — lower socioeconomic status and malnutrition are associated with BCS [1]
- Fluid restriction if hyponatremia develops
- Avoid alcohol — additional hepatotoxic insult in an already compromised liver
5. Review of Systems
- GI: Nausea, vomiting, anorexia, early satiety, abdominal pain, GI bleeding, diarrhea [10]
- Constitutional: Fatigue, weight loss (chronic) or weight gain (ascites)
- Hematologic: Easy bruising, petechiae, epistaxis (coagulopathy or thrombocytopenia from MPN/splenomegaly)
- Neurologic: Confusion, asterixis (hepatic encephalopathy)
- Skin: Pruritus, jaundice, spider angiomata
- Extremities: Bilateral lower extremity edema (IVC obstruction), scrotal varicosities [5]
- Pulmonary: Dyspnea (hepatic hydrothorax, hepatopulmonary syndrome)
6. Collateral History and Family History
- Family history of VTE, thrombophilia, or myeloproliferative neoplasms
- Inherited thrombophilias: Factor V Leiden (~8%), protein C/S deficiency, antithrombin deficiency — often familial [2]
- Pregnancy history: BCS can present during pregnancy or postpartum; fetal outcomes remain poor even when maternal outcomes are favorable [1]
- Medication history from family/pharmacy — confirm OCP use, anticoagulant compliance
- Social context: Occupational exposures, immigration status (geographic variation in etiology)
7. Risk Factors
Multiple prothrombotic conditions coexist in 25–46% of patients — even when one cause is identified, additional factors should be investigated. [2-3]
8. Differential Diagnosis
- Right-sided heart failure / constrictive pericarditis / tricuspid regurgitation: Hepatic congestion with ascites; echocardiography distinguishes [12]
- Sinusoidal obstruction syndrome (SOS/VOD): Especially post-HSCT or chemotherapy; similar congestion pattern but different clinical context
- Cirrhosis from other etiologies: Viral, alcoholic, NASH — BCS should be considered in any liver disease of unknown etiology [7]
- Portal vein thrombosis (without hepatic vein involvement)
- Hepatic malignancy with venous invasion (secondary BCS)
- IVC obstruction from tumor, membrane, or extrinsic compression
- Portosinusoidal vascular disease (formerly idiopathic portal hypertension): Can mimic chronic BCS with intrahepatic collaterals [2]
- Acute hepatitis (viral, drug-induced): Marked transaminase elevation may overlap with acute BCS
9. Past Medical History
- Prior VTE (DVT, PE, cerebral vein thrombosis, splanchnic vein thrombosis)
- Known myeloproliferative neoplasm or unexplained erythrocytosis/thrombocytosis
- Autoimmune disorders: Lupus, antiphospholipid syndrome, Behçet disease
- PNH diagnosis
- Prior abdominal surgery or trauma
- Chronic liver disease of unclear etiology — BCS may be the undiagnosed cause [7]
- Recurrent miscarriages (may suggest antiphospholipid syndrome)
10. Physical Exam
- Vital signs: Tachycardia, hypotension (if decompensated); fever uncommon unless superinfected ascites
- Abdomen:
- Hepatomegaly — often tender; caudate lobe hypertrophy may be palpable
- Ascites — shifting dullness, fluid wave
- Splenomegaly (portal hypertension or underlying MPN)
- Dilated abdominal wall veins — pattern may extend to flanks/back (IVC collaterals), distinct from typical caput medusae of portal hypertension [5]
- Extremities: Bilateral lower extremity edema (IVC obstruction), scrotal edema/varicosities
- Skin: Jaundice, spider angiomata, palmar erythema
- Neurologic: Asterixis, altered mental status (encephalopathy)
- Cardiac: Assess for JVD, murmurs — rule out right heart failure/constrictive pericarditis
11. Lab Studies
- Hepatic panel: AST/ALT (may be >1000 in acute; AST > ALT pattern), alkaline phosphatase, bilirubin (conjugated), albumin [12]
- Coagulation: PT/INR, aPTT, fibrinogen, factor V level (prognostic marker) [4]
- CBC with differential: Evaluate for erythrocytosis, thrombocytosis, leukocytosis (MPN clues) [2]
- BMP: Creatinine (hepatorenal syndrome), electrolytes
- Serum lactate: If concern for acute hepatic ischemia
- Ascitic fluid analysis: High SAAG (>1.1), total protein typically >2.5 g/dL (similar to cardiac ascites) [12]
- Thrombophilia workup (at diagnosis, per AASLD/ACG): [3][7]
- JAK2 V617F (first-line; if negative → JAK2 exon 12, CALR, MPL mutations) [2]
- Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, beta-2 glycoprotein)
- Flow cytometry for PNH
- Protein C, protein S, antithrombin levels (interpret cautiously with liver dysfunction — use ratios to other liver-synthesized proteins) [2]
- Factor V Leiden, prothrombin G20210A mutation
- AFP: Baseline for HCC surveillance [7]
12. Imaging
- First-line: Doppler ultrasound — sensitivity ~85–89% when performed by experienced operator [7][13]
- Confirmatory/Planning: Contrast-enhanced CT or MRI [3][7]
- Patchy "mosaic" parenchymal enhancement at arterial phase
- Absent hepatic vein opacification with preserved IVC enhancement
- Caudate lobe hypertrophy with heterogeneous liver morphology
- Venovenous collaterals (intrahepatic and extrahepatic)
- MRI has highest AUC (90.8%) for diagnosis [13]
- Hepatic venography: "Spiderweb pattern" — confirmatory when noninvasive imaging is equivocal; also used for interventional planning [12]
- When imaging is unnecessary: Liver biopsy alone is diagnostic only for small-vein BCS (~1% of cases) when gross hepatic veins are patent [2]
The following figure from the NEJM review demonstrates key imaging features of BCS including collateral vessels, caudate lobe enlargement, and successful angioplasty:
13. Special Tests
- Rotterdam BCS Prognostic Score: Uses ascites, encephalopathy, PT, and bilirubin to predict intervention-free survival; validated in European cohorts [3]
- BCS-TIPS Prognostic Index (BCS-PI): Age, bilirubin, INR — helps predict outcomes after TIPS [3]
- Liver elastography: Markedly elevated values due to congestion; can be used to monitor treatment response (values decrease as congestion improves) [2][7]
- Bone marrow biopsy: If MPN suspected but molecular testing equivocal
- Next-generation sequencing: Higher sensitivity for detecting low-allele-burden JAK2 mutations and noncanonical mutations missed by conventional testing [2]
- Intravascular ultrasound (IVUS): Aids in lesion characterization during interventional procedures; helps determine need for stenting vs. angioplasty alone [15]
14. ECG
- Not a primary diagnostic tool for BCS, but should be obtained to:
- Rule out right heart failure as a cause of hepatic congestion
- Assess for right atrial enlargement, right ventricular strain
- Evaluate for arrhythmias in the setting of electrolyte derangements from diuretic use or hepatorenal syndrome
- Echocardiography is more useful — rule out constrictive pericarditis, tricuspid regurgitation, right atrial myxoma [12]
15. Assessment
- Subacute presentation is most common: Insidious onset of ascites, hepatomegaly, and abdominal pain over weeks to months [3][5]
- Acute presentation: Rapid-onset abdominal pain, hepatomegaly, ascites, marked transaminase elevation (>1000), coagulopathy; may progress to fulminant liver failure [6]
- Chronic presentation: Discovered incidentally or presenting with complications of portal hypertension (variceal bleeding, refractory ascites); ~20% are asymptomatic at diagnosis [3]
- Severity stratification: Based on liver function (bilirubin, albumin, INR, factor V), renal function, presence of encephalopathy, and ascites response to diuretics [3-4]
- Complications: Portal hypertension, variceal bleeding, hepatorenal syndrome, hepatocellular carcinoma (annual incidence ~4% in Western populations), hepatic encephalopathy [4][7]
16. Treatment Plan
The ACG and AASLD recommend a stepwise "step-up" approach from least to most invasive: [3][7]
Step 1 — Medical Therapy (all patients)
- Anticoagulation: LMWH initially → transition to warfarin (target INR 2–3); avoid long-term UFH [2][7]
- Treat underlying cause: Cytoreduction for MPN, eculizumab for PNH, immunosuppression for antiphospholipid syndrome [2]
- Portal hypertension management: Diuretics (spironolactone ± furosemide), nonselective beta-blockers, therapeutic paracentesis [2]
- ~44% of patients can be managed with medical therapy alone [3]
Step 2 — Angioplasty ± Stenting (if medical therapy fails)
- For short-segment hepatic vein or IVC stenosis/web [2]
- Angioplasty first; stenting reserved for angioplasty failure (stenting may compromise future TIPS) [2]
- More effective in Asian populations with IVC-predominant disease (>70% success) vs. European populations (~10%) [2]
Step 3 — TIPS or DIPS (if angioplasty fails or not feasible)
- PTFE-covered stents preferred [6-7]
- 5-year transplant-free survival: 72–78% [2-3]
- Direct transcaval approach (DIPS) required in >40% of BCS patients due to inability to access remnant hepatic veins [2]
- Should be performed at tertiary centers with expertise [2][7]
Step 4 — Liver Transplantation (last resort)
- Reserved for TIPS failure or fulminant liver failure [3][7]
- 5-year post-transplant survival: 70–92% [3]
- TIPS can serve as bridge to transplantation [2][7]
- Lifelong anticoagulation post-transplant recommended (recurrent thrombosis in up to 20%) [3]
17. Disposition
- Admit (all acute/subacute presentations):
- Fulminant liver failure → ICU, early transplant listing
- New-onset ascites with liver dysfunction
- GI bleeding from varices
- Hepatic encephalopathy
- Need for initiation of anticoagulation with monitoring
- Early referral to a tertiary liver center with multidisciplinary expertise (hepatology, interventional radiology, transplant surgery, hematology) is strongly recommended [2][7]
- Specialist consultation triggers:
- Hematology: All patients at diagnosis for thrombophilia workup [7]
- Interventional radiology/hepatology: If medical therapy fails (worsening liver/renal function, refractory ascites, encephalopathy) [3]
- Transplant surgery: If TIPS fails or fulminant presentation [7]
- Observation/outpatient: Chronic BCS discovered incidentally with stable liver function — can initiate anticoagulation and workup as outpatient with close follow-up
18. Follow Up / Return Precautions
- Close monitoring of clinical, biochemical, and imaging features — no validated timeline exists for escalating therapy; decisions are based on clinical trajectory [2]
- Anticoagulation monitoring: INR (if on warfarin), renal function, CBC
- HCC surveillance: Ultrasound ± AFP every 6 months (as in cirrhosis); HCC diagnosis in BCS should require histological confirmation due to perturbed vascularity [7]
- Liver elastography: Can track treatment response (decreasing values indicate improving congestion) [7]
- Return precautions (patient counseling):
- Increasing abdominal swelling, new or worsening jaundice
- Vomiting blood or black tarry stools
- Confusion or excessive drowsiness
- Fever with abdominal pain (spontaneous bacterial peritonitis)
- Signs of bleeding (anticoagulation-related)
- Expected course: With stepwise management, 5-year overall survival is approximately 77–82%. Most patients require lifelong anticoagulation. [1-4]
References
1. Budd Chiari Syndrome: Presentation, Management, and Prognosis. — Amjad W, Thuluvath PJ. The American Journal of Gastroenterology. 2025.
2. Primary Budd–Chiari Syndrome. — Garcia-Pagán JC, Valla DC. The New England Journal of Medicine. 2023.
3. ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. — Simonetto DA, Singal AK, Garcia-Tsao G, et al. The American Journal of Gastroenterology. 2020.
4. Hepatic Venous Outflow Syndromes and Splanchnic Venous Thrombosis. — Laure Elkrief, Dominique Valla Evidence‐based Gastroenterology and Hepatology 4e. 2019.
5. Interventions in Budd-Chiari Syndrome: An Updated Review. — Patel RK, Chandel K, Tripathy T, et al. Abdominal Radiology. 2025.
6. Acute Liver Failure Guidelines. — Shingina A, Mukhtar N, Wakim-Fleming J, et al. The American Journal of Gastroenterology. 2023.
7. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. — Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Hepatology. 2021.
8. Budd-Chiari Syndrome: Investigation, Treatment and Outcomes. — Goel RM, Johnston EL, Patel KV, Wong T. Postgraduate Medical Journal. 2015.
9. Splanchnic Vein Thrombosis and Myeloproliferative Neoplasms: Molecular-Driven Diagnosis and Long-Term Treatment. — De Stefano V, Qi X, Betti S, Rossi E. Thrombosis and Haemostasis. 2016.
10. Cancer-Associated Venous Thromboembolic Disease. — Updated 2026-05-05. National Comprehensive Cancer Network.
11. Myeloproliferative Neoplasms in Budd-Chiari Syndrome and Portal Vein Thrombosis: A Meta-Analysis. — Smalberg JH, Arends LR, Valla DC, et al. Blood. 2012.
12. The Budd–Chiari Syndrome. — Menon KV, Shah V, Kamath PS. The New England Journal of Medicine. 2004.
13. Diagnostic Accuracy of Doppler Ultrasound, CT and MRI in Budd Chiari Syndrome: Systematic Review and Meta-Analysis. — Gupta P, Bansal V, Kumar-M P, et al. The British Journal of Radiology. 2020.
14. Ultrasound Characteristics of Budd-Chiari Syndrome: A Multicenter Analysis. — Daza J, Wiest I, Cui XW, et al. Digestive Diseases. 2024.
15. Budd-Chiari Syndrome: Update on Classification and Intravascular US. — Sailer A, Nezami N, Tabeli Bouroujeni P, et al. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 2025.